Fuzhou Pulmonary Hospital of Fujian

Clinical utility of molecular residual disease detection in early-stage resected EGFR-mutated non-small cell lung cancer

Molecular residual disease (MRD), detected through circulating tumor DNA, has emerged as a promising biomarker for surveillance in patients with early-stage non-small cell lung cancer (NSCLC) following curative-intent resection. Here we report the MRD analysis from the phase 3 EV...